NCT06092853

Brief Summary

Metabolic syndrome and periodontitis are diseases that lower the quality of life and their incidence rates are increasing. Since both of these diseases are associated with systemic inflammation and insulin resistance, they may be comorbid. The aim of this study was to evaluate the effect of interleukin-20 (IL-20) on periodontal destruction in individuals with metabolic syndrome while considering the relationship between metabolic syndrome and periodontitis. This study included a total of 80 individuals who were systemically and periodontally healthy (CG, n=20), were systemically healthy and had periodontitis (PG, n=20), had metabolic syndrome and were periodontally healthy (MG, n=20), or had both metabolic syndrome and periodontitis (MPG, n=20). Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 6, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 6, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2023

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 10, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

October 23, 2023

Completed
Last Updated

October 23, 2023

Status Verified

October 1, 2023

Enrollment Period

9 months

First QC Date

October 10, 2023

Last Update Submit

October 16, 2023

Conditions

Keywords

Metabolic syndromeperiodontitisinterleukin-20

Outcome Measures

Primary Outcomes (2)

  • concentration of gingival crevicular fluid (GCF) parameters

    interleukin-20, RANKL, OPG values evaluated in GCF.

    1 year

  • concentration of serum parameters

    interleukin-20, RANKL, OPG, MMP-8, TOS, TAS values evaluated in serum

    1 year

Secondary Outcomes (2)

  • value of periodontal clinical parameters

    1 year

  • value of patients' clinical metabolic syndrome parameters

    1 year

Study Arms (4)

systemically and periodontally healthy (CG)

Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses.

Other: Gingival crevicular fluid (GCF) and serum samples

systemically healthy and periodontitis (PG)

Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses

Other: Gingival crevicular fluid (GCF) and serum samples

Metabolic syndrome and periodontally healthy (MG)

Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses

Other: Gingival crevicular fluid (GCF) and serum samples

Metabolic syndrome and periodontitis (MPG)

Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses

Other: Gingival crevicular fluid (GCF) and serum samples

Interventions

Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses

Metabolic syndrome and periodontally healthy (MG)Metabolic syndrome and periodontitis (MPG)systemically and periodontally healthy (CG)systemically healthy and periodontitis (PG)

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The sample size of the study was calculated using the G\*Power program with an effect size of 0.4, 80% power, and a margin of error of 0.05.

You may qualify if:

  • all participants were required to have at least 20 teeth and be between the ages of 20 and 65 years

You may not qualify if:

  • Smokers, patients who had used antibiotics or anti-inflammatory and antioxidant drugs in the last 6 months, patients who were pregnant or lactating, those who had cancer or autoimmune diseases, and those who had undergone any periodontal treatment in the last 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Recep Tayyip Erdogan University

Rize, Turkey (Türkiye)

Location

Related Publications (1)

  • Senkal R, Yemenoglu H, Kose O, Karakas SM, Yilmaz A, Akyildiz K, Beder M, Bostan SA. The role of interleukin-20 on inflammatory stress and periodontal tissue destruction in patients with metabolic syndrome and periodontitis. BMC Oral Health. 2024 Nov 22;24(1):1423. doi: 10.1186/s12903-024-05224-3.

Biospecimen

Retention: SAMPLES WITH DNA

plasma and gingival crevicular fluid

MeSH Terms

Conditions

InflammationMetabolic SyndromePeriodontitis

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsInsulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesPeriodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
1 Week
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

October 10, 2023

First Posted

October 23, 2023

Study Start

June 6, 2022

Primary Completion

March 6, 2023

Study Completion

June 6, 2023

Last Updated

October 23, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations